RxDoctor Payments Data

Silvia Urbina

Internal Medicine · San Diego, CANPI 1588930895

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by AbbVie at 39.1% of the total. Reporting peaked in 2021 at $193 and has fallen 51.1% since, to $94 in 2022.

$371in general payments, 2019–2025

Across 5 payments — averaging $74.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$145
  • AstraZeneca$116
  • Takeda Pharmaceuticals U.S.A., Inc.$94
  • Intercept Pharmaceuticals, Inc.$16
$1,709,724in research payments, 2019–2025

Across 29 payments — averaging $58,956 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dexcom, Inc.$1.5M
  • Astrazeneca UK Limited$258K

What the payments were for

  • Food & beverage$371100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$371 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Other internal medicine in San Diego

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →